Transgenomic Eyes Dana-Farber's COLD-PCR for Cancer Screening Applications | GenomeWeb

NEW YORK (GenomeWeb News) – Transgenomic believes that a new PCR technology that it recently licensed from the Dana-Farber Cancer Institute could have promise down the road as a screening tool to detect early-stage cancer in blood samples.

The technology, called coamplification at lower denaturation temperature PCR, or COLD-PCR, was developed by Mike Makrigiorgos' lab at Dana-Farber. It preferentially amplifies segments of DNA that contain mutations, and is thereby able to increase the sensitivity of downstream mutation-detection methods by a factor of 10 to 100.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.

The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.

The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.

In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.